Peer-reviewed veterinary case report
Testing mupirocin and novobiocin on resistant and susceptible staph
By Fulham, Kristen S et al.·Published in Veterinary dermatology·2011·Department of Dermatology, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: In vitro susceptibility testing of meticillin-resistant and meticillin-susceptible staphylococci to mupirocin and novobiocin.
- Species:
- dog
Plain-English summary
A study found that mupirocin, a topical treatment for bacterial skin infections, and novobiocin, an oral medication for upper respiratory infections, can be effective against certain types of staphylococci bacteria in dogs. Researchers tested samples from healthy dogs and those with skin infections (superficial pyoderma) and discovered that a high percentage of both meticillin-susceptible (MSS) and meticillin-resistant staphylococci (MRS) were susceptible to these treatments. Specifically, mupirocin worked well for nearly all MSS and most MRS isolates, while novobiocin was effective for the majority of MSS and a good portion of MRS isolates. This suggests that both medications could be useful options for treating bacterial infections in dogs.
People also search for: dog skin infection treatment · mupirocin for dogs · novobiocin for dog respiratory infection · staphylococcus in dogs · dog pyoderma treatment
Abstract
Antimicrobials effective against meticillin-resistant staphylococci are limited. Mupirocin is a topical antimicrobial used to treat bacterial skin infections. Novobiocin is an oral antimicrobial approved for treatment of staphylococcal upper respiratory infections in dogs. This study reports the in vitro activity of mupirocin and novobiocin on meticillin-susceptible (MSS) and resistant staphylococci (MRS) from healthy dogs and dogs with superficial pyoderma. Staphylococci were isolated from skin swabs at four sites on healthy dogs and from lesions on dogs with superficial pyoderma. Staphylococci were identified by morphology and by catalase and coagulase testing. Speciation and susceptibility testing were performed by the Dade Microscan (W. Sacramento, CA, USA). Meticillin resistance was confirmed by an oxacillin screen plate. Novobiocin and mupirocin susceptibilities were tested by disc diffusion. Staphylococci were cultured from 61 healthy dogs (17 MRS and 44 MSS) and 30 dogs with pyoderma (15 MRS and 15 MSS), with higher proportions of MRS isolates in dogs with pyoderma (P=0.038; χ(2) test). For mupirocin, 79.5% (35 of 44) MSS and 82.3% (14 of 17) MRS isolates from healthy dogs, and 100% (15 of 15) MSS and 86.6% (13 of 15) MRS isolates from dogs with pyoderma were susceptible (MSS, P=0.094; MRS, P=1.0; Fisher's exact test). For novobiocin, 95.4% (42 of 44) MSS and 52.9% (nine of 17) MRS isolates from healthy dogs and 93.3% (14 of 15) MSS and 80% (12 of 15) MRS isolates from dogs with pyoderma were susceptible (MSS, P=1.0; MRS, P=0.148; Fisher's exact test).
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/21039985/